Agreement with Abbott Laboratories New Zealand Limited for the supply of interventional cardiology products
21 May 2015
PHARMAC is pleased to announce the approval of an agreement with Abbott Laboratories New Zealand Limited (Abbott) for the supply of Interventional Cardiology products.
In summary, the effect of the decision is that:
- A range of Interventional Cardiology products will be listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule from 1 June 2015.
- DHB hospitals can purchase these items either directly from Abbott or through a designated third party logistics provider under the national agreement.
- For the DHBs that currently use these products the national agreement will deliver savings.
Details of the decision
Following a Registration of Interest document issued in April 2014, PHARMAC has entered into an agreement with Abbott Laboratories New Zealand Limited for the supply of a selection of Interventional Cardiology products to be listed on the Pharmaceutical Schedule. This means that DHB hospitals may purchase these products under the national agreement at the new pricing.
The list of products is available on PHARMAC’s website in the Pharmaceutical Schedule, Section H, Part 3 in both a PDF document and a series of Excel spreadsheets.
There are estimated savings to DHBs that currently use these products of approximately $310,000 per annum nationally, based on current usage.
The agreement is not exclusive. DHBs can continue to purchase other brands of Interventional Cardiology products at their discretion.
Educational services will be provided by Abbott to DHB personnel on appropriate use of its Interventional Cardiology products and will be arranged in a format and times as agreed with individual DHBs.
If you have any questions about this decision you can email PHARMAC at email@example.com or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 16 July 2020